Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) EPS (Weighted Average and Diluted) (2016 - 2025)

Capricor Therapeutics has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at -$0.62 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 463.64% year-over-year to -$0.62; the TTM value through Dec 2025 reached -$2.26, down 96.52%, while the annual FY2025 figure was -$2.26, 96.52% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.62 at Capricor Therapeutics, down from -$0.54 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.02 in Q4 2023 and troughed at -$0.62 in Q4 2025.
  • A 5-year average of -$0.31 and a median of -$0.3 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 106.45% in 2023 and later tumbled 650.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.26 in 2021, then decreased by 19.23% to -$0.31 in 2022, then skyrocketed by 106.45% to $0.02 in 2023, then tumbled by 650.0% to -$0.11 in 2024, then crashed by 463.64% to -$0.62 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CAPR at -$0.62 in Q4 2025, -$0.54 in Q3 2025, and -$0.57 in Q2 2025.